DiagnoCure buys Catalyst diagnostics technology in $3m cash-and-stock deal:
This article was originally published in Clinica
Diagnostics and lab services specialist DiagnoCure has acquired Catalyst Oncology (Worcester, Massachusetts), gaining access to the latter's prognostic tests for cancer, including breast and colon. The deal sees Quebec City, Canada-based DiagnoCure pay a $3m mix of cash and shares upfront, and potential milestone payments at a later date. Although Catalyst's tests have been validated in clinical studies involving five tumour types, DiagnoCure intends to develop the technology by conducting additional clinical studies.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.